López-Rubio, Carlos
Koponen, Marjaana
Lampela, Pasi
Taipale, Heidi
Tanskanen, Antti
Bell, J. Simon
Tolppanen, Anna-Maija
Hartikainen, Sirpa
Article History
Received: 8 June 2021
Accepted: 29 November 2021
First Online: 15 December 2021
Declarations
:
: Register maintainers have approved the MEDALZ study plan. Data were pseudonymized before submission to the research team and study participants were not contacted. Therefore, according to Finnish legislation (including Personal Data Act 23/1999, Act on the Openness of Government Activities 621/1999 and Act on the Secondary Use of Health and Social Data 552/2019 (and previous Act on the National Healthcare registers, not official English translation as this is not available 556/1989) the study has been granted an exemption from requiring ethics approval or informed consent.
: Not applicable.
: CLR, MK, PL, A-MT have no conflicts of interest. SH has got lecture fees from Astellas-Pharma. HT and AT have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. HT reports personal fees from Janssen-Cilag. JSB has received grant funding from the Australian National Health and Medical Research Council (NHMRC), Medical Research Future Fund (MRFF), Victorian Government Department of Health and Human Services (DHHS), Dementia Australia Research Foundation (DARF), Dementia Centre for Research Collaboration (DCRC), Yulgilbar Foundation, Pharmaceutical Society of Australia (PSA), GlaxoSmithKline Supported Studies Programme, and several aged care provider organizations over the past three years all unrelated to the present work. All grants and consulting funds were paid to the employing institution. JSB is supported by a NHMRC Boosting Dementia Leadership Fellowship.